Semaglutide is made through a combination of biotechnology and chemical engineering. The process starts with genetically modified bacteria that produce a protein backbone, which is then chemically modified to create a molecule that lasts far longer in the human body than the natural hormone it mimics. From fermentation to final purification, manufacturing semaglutide requires precise, multi-step production that helps explain both its effectiveness and its cost.
Starting With a Natural Hormone
Semaglutide is a modified version of GLP-1, a hormone your gut releases after eating to signal fullness and regulate blood sugar. The problem with natural GLP-1 is that it breaks down in minutes. An enzyme called DPP-4 chews it apart almost immediately, making it useless as a drug on its own.
To solve this, researchers redesigned the molecule. Semaglutide shares 94% of its structure with human GLP-1, built from 31 amino acids, but with two key substitutions. At position 8, a natural amino acid is swapped for a synthetic one that resists breakdown by DPP-4. At position 34, another substitution prevents the fatty acid side chain (added later) from attaching in the wrong spot. These small changes transform a fragile hormone into a durable drug with a half-life of about one week, roughly 155 hours, which is why it only needs to be taken once weekly.
Growing the Peptide Backbone in Bacteria
The core protein chain of semaglutide is produced using recombinant DNA technology, the same general approach used to make insulin. Scientists insert the gene encoding a semaglutide precursor into E. coli bacteria, specifically a strain called BL21(DE3) that is widely used in pharmaceutical manufacturing. The gene is loaded onto a circular piece of DNA called a plasmid and introduced into the bacterial cells.
These engineered bacteria are then grown in large fermentation tanks through a process called high-density fermentation. As the bacteria multiply, they produce the semaglutide precursor protein in bulk. The protein accumulates inside the bacterial cells in dense clusters called inclusion bodies. Once fermentation is complete, the cells are broken open and these inclusion bodies are collected as the raw starting material for the next steps.
Attaching the Fatty Acid Side Chain
The bacterial fermentation only produces the peptide backbone. What makes semaglutide last a full week in the body is a fatty acid “tail” that gets attached through a separate chemical reaction after the protein is harvested.
This tail is a C18 fatty diacid, an 18-carbon fatty acid chain with acid groups at both ends. It connects to the peptide at position 26 through a small molecular spacer made of a glutamic acid and two short chemical links. The spacer and fatty acid together act like an anchor: once semaglutide enters the bloodstream, the fatty tail grabs onto albumin, the most abundant protein in blood. Bound to albumin, semaglutide is shielded from being filtered out by the kidneys or broken down by enzymes, dramatically extending its active life.
Researchers at Novo Nordisk tested fatty acid chains ranging from 12 to 20 carbons long before settling on the C18 diacid. It offered the best combination of strong albumin binding and potent activation of the GLP-1 receptor.
Purification to Pharmaceutical Grade
After the peptide backbone is produced and the fatty acid chain attached, the resulting mixture contains the target molecule along with byproducts, incomplete molecules, and impurities. Getting from this crude mixture to a pharmaceutical-grade ingredient requires multiple rounds of purification.
The crude semaglutide is first dissolved in a buffered solution, then passed through a fine filter to remove particles. It then goes through at least two rounds of a technique called reversed-phase chromatography, which separates molecules based on how they interact with a specially coated silica material. In the first round, the goal is to collect fractions with purity above 95%. In the second round, using slightly different conditions, purity is pushed above 99.5%, with any single remaining impurity held below 0.1%. The purified solution is then concentrated and freeze-dried into a stable powder, the active pharmaceutical ingredient ready to be formulated into the final drug product.
Making an Oral Version
Most peptide drugs can only be injected because stomach acid and digestive enzymes destroy them. The oral form of semaglutide (sold as Rybelsus) solves this with an absorption enhancer called SNAC, which is co-formulated into each tablet.
SNAC works through three mechanisms simultaneously. It acts as a local buffer around the tablet, neutralizing stomach acid in the immediate area and protecting semaglutide from being degraded by gastric enzymes. It also prevents semaglutide molecules from clumping together, which would make them too large to absorb. Finally, SNAC interacts with the lipid membranes of stomach lining cells, temporarily making them more permeable so semaglutide can pass through into the bloodstream. Importantly, it does this without disrupting the tight junctions between cells, so the effect is localized and reversible. Even with SNAC, oral bioavailability is low compared to injection, which is why the oral tablets require specific dosing conditions like taking them on an empty stomach with only a small amount of water.
Where Semaglutide Is Manufactured
Novo Nordisk, the company that developed and holds the patents for semaglutide, operates 16 major production sites across Denmark, the United States, France, China, and Brazil, along with smaller facilities in other countries. The surge in demand for semaglutide products, sold under the brand names Ozempic (for type 2 diabetes), Wegovy (for weight management and cardiovascular risk reduction), and Rybelsus (the oral formulation), has driven massive expansion of manufacturing capacity. The production process is complex enough that scaling up takes years, involving not just building new facilities but validating every step of the biological and chemical manufacturing chain to meet regulatory standards.
Wegovy alone now carries FDA-approved indications for weight loss in adults and adolescents 12 and older with obesity, cardiovascular risk reduction in adults with established heart disease, and treatment of a form of fatty liver disease called MASH with moderate to advanced scarring. Each new indication further increases demand on an already strained manufacturing pipeline.